To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04745832
Title Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors MEI Pharma, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | TUR | POL | NZL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | CAN | BEL | AUS


No variant requirements are available.